Study guide
8.2 Physical and Chemical Incompatibilities: pH Effects, Salt Formations & Precipitation Mechanisms
BCSCP Board Certified Sterile Compounding Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview, USP Standards & CSP Categories
1.1 BCSCP Exam Format, Eligibility, Scoring & 2024 Content Outline 1.2 USP <797> Scope, Core Philosophy & Regulatory Framework 1.3 USP <797> Categories 1, 2, and 3 CSP Classification 1.4 Immediate-Use CSPs: The 4-Hour Rule and Its Conditions
2 Chapter 2: Facilities, Engineering Controls & Cleaning
2.1 Cleanroom Architecture & ISO Classifications 2.2 Primary Engineering Controls (PECs) & Laminar Airflow Dynamics 2.3 Segregated Compounding Areas (SCAs) & Containment SCAs (C-SCAs) 2.4 HVAC Engineering Controls, Pressure Differentials & Air Exchange 2.5 Equipment & Materials in Classified Areas Under Dynamic Conditions 2.6 Cleaning, Disinfecting, Sporicidal Agents & Sterile 70% IPA 2.7 Contingency Planning: Power, HVAC, Supply and Staffing Failures
3 Chapter 3: Environmental Monitoring & Facility Certification
3.1 Viable Airborne Microbial Monitoring 3.2 Total Airborne Non-Viable Particle Counting & Cleanroom Certification Standards 3.3 Surface Microbial Sampling: Contact Plates, Swabs, Incubation Protocols & Action Levels 3.4 Environmental Sampling Excursions, Trend Analysis, and Remediation Protocols
4 Chapter 4: Hand Hygiene, Garbing & Aseptic Technique
4.1 Hand Hygiene & Cleansing Protocols 4.2 Step-by-Step Garbing Sequence & Ante-Room Logistics 4.3 Direct Compounding Area (DCA) Aseptic Technique & First Air Integrity
5 Chapter 5: Beyond-Use Dating, Storage & Container Rules
5.1 Category 1 Beyond-Use Dating & Storage Limitations 5.2 Category 2 Beyond-Use Dating: Sterile vs. Nonsterile Starting Components 5.3 Category 3 Beyond-Use Dating: Requirements for Extended Dating (60/90/120 Days) 5.4 Container Types, Puncture Limits & Multi-Dose Container Rules
6 Chapter 6: Sterilization, Release Testing & Hazardous Drug Compounding
6.1 Terminal Sterilization vs. Sterilizing Filtration 6.2 Release Testing: Sterility (USP <71>), Endotoxin (USP <85>) & Particulates (USP <788>) 6.3 Container Closure Integrity Testing (CCIT) & Visual Inspection 6.4 USP <800> Hazardous Drug Compounding & Closed System Drug-Transfer Devices (CSTDs)
7 Chapter 7: Materials, Equipment & Compounding Workflow
7.1 Compounding Equipment & Technology: ACDs, Balances, Pumps & IV Workflow Systems 7.2 Compounding Supplies, Containers & Closures 7.3 Component Receipt, Storage & Material Transfer 7.4 Calibration, Verification, Validation & Maintenance of Equipment 7.5 Compounding Workflow: SOPs, Workflow Software, Production Queues & Labeling 7.6 Handling, Storing, Packaging, Transporting & Disposing of Finished CSPs
8 Chapter 8: Calculations, Osmolarity & Physicochemical Compatibility
8.1 Sterile Compounding Calculations: Millimoles, Milliequivalents, Osmolarity & Tonicity Adjustments 8.2 Physical and Chemical Incompatibilities: pH Effects, Salt Formations & Precipitation Mechanisms 8.3 Complex Admixture Compatibility: Calcium-Phosphate Solubility Curves & Parenteral Nutrition Dynamics
9 Chapter 9: Therapeutics, Administration & Patient Monitoring
9.1 Patient-Specific Parameters: Verifying CSP Orders 9.2 Special Administration Routes: Epidural, Intrathecal, Ophthalmic & Intravesical Sterile Preparations 9.3 Medication Delivery Devices, Home Infusion & Patient Education 9.4 High-Alert Sterile Medications, Pediatric/Neonatal Considerations & Extravasation Management 9.5 Therapeutic Drug Monitoring, Catheter-Related Bloodstream Infection (CRBSI) Prevention & Clinical Vigilance 9.6 Medication Adherence in Home and Outpatient Sterile Therapy 9.7 Interprofessional Care Coordination for Sterile Preparations
10 Chapter 10: Quality Management, Records & Personnel Competency
10.1 Master Formulation Records (MFR) vs. Compounding Records (CR) Requirements & Workflow 10.2 Personnel Training, Core Competency & Written Testing Requirements 10.3 Gloved Fingertip and Thumb Sampling (GFT) Testing Cadence, Pass/Fail Thresholds & Action Plans 10.4 Media-Fill Testing Protocols: Simulation Design, Incubation Parameters & Failure Investigations 10.5 Standard Operating Procedures & Document Control 10.6 Quality Assurance & Quality Control Programs 10.7 Inspection Methods, Self-Audits & Continuous Readiness 10.8 Literature Evaluation: Research Methods, Statistics & Stability Evidence
11 Chapter 11: Regulatory Oversight, Accreditation & Drug Supply Chain
11.1 Drug Quality and Security Act (DQSA) & FDA Section 503A Traditional Pharmacies vs. Section 503B Outsourcing Facilities 11.2 State Boards of Pharmacy, FDA Guidance & Inter-Agency Regulatory Jurisdictions 11.3 Drug Supply Chain Security Act (DSCSA), Component Qualification & Certificate of Analysis (CoA) Verification 11.4 CMS, The Joint Commission, CDC, ASPEN & ASHP: Standards Beyond USP and FDA
12 Chapter 12: Safety Management, Investigations, Recalls & Waste
12.1 Root Cause Analysis (RCA), CAPA Framework & Out-of-Specification (OOS) Investigations 12.2 Adverse Drug Event Reporting, FDA MedWatch Form 3500 & Product Recall Protocols 12.3 Occupational Safety, Hazardous Waste Disposal (RCRA / EPA) & Spill Clean-up Management
8.2 Physical and Chemical Incompatibilities: pH Effects, Salt Formations & Precipitation Mechanisms
Key Takeaways Explain This Topic AI
Physical incompatibilities produce macroscopically observable phase alterations—such as crystalline precipitation, acid-base neutralization insolubility, co-solvent dilution collapse, phase separation (cracking of lipid emulsions), and effervescence—without initially cleaving covalent chemical bonds.
Under the Henderson-Hasselbalch relationship, weak acid drugs (e.g., sodium phenytoin, furosemide, phenobarbital) precipitate as insoluble free acids in acidic diluents ( pH < 7.0 \text{pH} < 7.0 pH < 7.0 ), whereas weak base drugs (e.g., midazolam, ondansetron, morphine) precipitate as insoluble free bases when exposed to alkaline environments.
Chemical incompatibilities result in irreversible molecular degradation, primarily mediated by hydrolysis (cleavage of beta-lactam rings and ester bonds accelerated by heat and non-neutral pH), oxidation (free-radical degradation of catecholamines requiring antioxidant buffers and headspace inerting), and photolysis (light-activated breakdown of sodium nitroprusside requiring immediate light shielding).
Lipophilic drugs (nitroglycerin, diazepam, amiodarone, lorazepam) undergo significant sorption to polyvinyl chloride (PVC) surfaces, while lipid vehicles and surfactant excipients (Cremophor EL, polysorbate 80) leach toxic di(2-ethylhexyl) phthalate (DEHP) plasticizers from PVC, mandating polyolefin, glass, and dedicated in-line filtration ( 0.22 μ m 0.22\,\mu\text{m} 0.22 μ m for crystalloids, 1.2 μ m 1.2\,\mu\text{m} 1.2 μ m for lipid admixtures, 5 μ m 5\,\mu\text{m} 5 μ m for ampules).
Last updated: September 2026
8.2 Physical and Chemical Incompatibilities: pH Effects, Salt Formations & Precipitation Mechanisms
Note
Clinical Core: Incompatibilities between intravenous admixtures represent severe clinical threats. Physical precipitation can result in systemic microvascular pulmonary embolism, catastrophic multi-organ infarction, or immediate occlusion of life-sustaining vascular lines. Chemical degradation can lead to therapeutic failure from sub-potent active drugs or acute toxicities from degradation byproducts. A board-certified sterile compounding specialist must understand the underlying thermodynamics of ionization, solubility products, polymer interactions, and degradation kinetics to engineer stable, biocompatible parenteral formulations.
Diagnostic Taxonomy: Physical vs. Chemical Incompatibility
Sterile admixture incompatibilities fall into two fundamentally distinct scientific categories:
Physical Incompatibilities: A macroscopic, visible, or colligative phase change occurring upon the combination of two or more substances. Physical incompatibilities alter the state of matter (e.g., solid-liquid phase changes, gas evolution, or immiscibility) but do not initially involve the cleavage or synthesis of covalent molecular bonds. Physical events include crystalline precipitation, co-solvent dilution collapse, phase separation (lipid emulsion cracking), and sorption onto container surfaces.
Chemical Incompatibilities: An irreversible chemical reaction that alters the covalent architecture of the drug molecule, creating distinct degradation products. Chemical incompatibilities are often completely invisible to visual inspection —a crystal-clear, colorless solution may suffer a 50 % 50\% 50% loss in potency within hours due to active-site cleavage. The primary chemical mechanisms are hydrolysis, oxidation-reduction, photolysis, and covalent polymerization.
- Physical Incompatibilities: Mechanisms of Precipitation & Phase Collapse
- 1. pH-Dependent Ionization & Acid-Base Precipitation
Most parenteral drugs are formulated as water-soluble salts of weak organic acids or weak organic bases. In aqueous solution, weak electrolytes exist in dynamic equilibrium between their ionized (polar, charged, hydrophilic, water-soluble) form and their unionized (non-polar, uncharged, lipophilic, poorly water-soluble) free form.
This thermodynamic balance is described by the Henderson-Hasselbalch equations :
For Weak Acids: pH = p K a + log ( [ A − ] [ HA ] ) ⟺ [ A − ] [ HA ] = 10 ( pH − p K a ) \text{For Weak Acids: } \text{pH} = \text{p}K_a + \log\left(\frac{[\text{A}^-]}{[\text{HA}]}\right) \iff \frac{[\text{A}^-]}{[\text{HA}]} = 10^{(\text{pH} - \text{p}K_a)} For Weak Acids: pH = p K a + lo g ( [ HA ] [ A − ] ) ⟺ [ HA ] [ A − ] = 1 0 ( pH − p K a )
For Weak Bases: pH = p K a + log ( [ B ] [ BH + ] ) ⟺ [ B ] [ BH + ] = 10 ( pH − p K a ) \text{For Weak Bases: } \text{pH} = \text{p}K_a + \log\left(\frac{[\text{B}]}{[\text{BH}^+]}\right) \iff \frac{[\text{B}]}{[\text{BH}^+]} = 10^{(\text{pH} - \text{p}K_a)} For Weak Bases: pH = p K a + lo g ( [ BH + ] [ B ] ) ⟺ [ BH + ] [ B ] = 1 0 ( pH − p K a )
Where:
[ A − ] [\text{A}^-] [ A − ] is the water-soluble ionized conjugate base; [ HA ] [\text{HA}] [ HA ] is the insoluble unionized free acid.
[ BH + ] [\text{BH}^+] [ BH + ] is the water-soluble ionized conjugate acid; [ B ] [\text{B}] [ B ] is the insoluble unionized free base. WEAK ACID DRUGS (Phenytoin, Furosemide) WEAK BASE DRUGS (Midazolam, Morphine)
- ┌─────────────────────────────────────────────┐ ┌─────────────────────────────────────────────┐
- │ High pH (> 8-12) ──► Fully Ionized [A-] │ │ Low pH (< 3-5) ──► Fully Ionized [BH+] │
- │ (Water Soluble - Stable Commercial Vial) │ │ (Water Soluble - Stable Commercial Vial) │
- ├─────────────────────────────────────────────┤ ├─────────────────────────────────────────────┤
- │ Acidic Diluent (D5W / NS) ──► pH Drops │ │ Alkaline Diluent (NaHCO3) ──► pH Rises │
- │ Precipitates as INSOLUBLE FREE ACID [HA]! │ │ Precipitates as INSOLUBLE FREE BASE [B]! │
- └─────────────────────────────────────────────┘ └─────────────────────────────────────────────┘
- Weak Acid Precipitation in Acidic Environments
Phenytoin Sodium: Phenytoin is an extremely weak acid ( p K a ≈ 8.3 \text{p}K_a \approx 8.3 p K a ≈ 8.3 ). Commercial phenytoin injection is formulated at a caustic pH \text{pH} pH of 12.0 12.0 12.0 using 40 % 40\% 40% propylene glycol and 10 % 10\% 10% ethanol to force the drug into its ionized conjugate base ( [ A − ] [\text{A}^-] [ A − ] ). When phenytoin is introduced into an acidic IV fluid like 5 % Dextrose 5\%\,\text{Dextrose} 5% Dextrose ( pH ≈ 4.0 − 4.5 \text{pH} \approx 4.0-4.5 pH ≈ 4.0 − 4.5 ), the local pH \text{pH} pH drops precipitously below its p K a \text{p}K_a p K a . Protons force the equilibrium backward toward unionized free phenytoin ( [ HA ] [\text{HA}] [ HA ] ), which has an aqueous solubility of only a few tens of micrograms per milliliter. Needle-like macroscopic crystals instantly shower out of solution.
Furosemide: Formulated as a sodium salt at pH 8.5 to 9.3 \text{pH } 8.5\text{ to }9.3 pH 8.5 to 9.3 . Combining furosemide with acidic infusions (e.g., milrinone, midazolam, or dopamine) neutralizes the carboxylate ion, causing instantaneous precipitation of insoluble free furosemide.
Weak Base Precipitation in Alkaline Environments
Midazolam Hydrochloride, Ondansetron HCl, Morphine Sulfate: These basic drugs are formulated as salts of strong acids (hydrochlorides or sulfates) at acidic pH ( 3.0 to 4.0 ) \text{pH } (3.0\text{ to }4.0) pH ( 3.0 to 4.0 ) to ensure complete protonation into [ BH + ] [\text{BH}^+] [ BH + ] . If mixed with alkaline solutions—such as 8.4 % Sodium Bicarbonate 8.4\%\,\text{Sodium Bicarbonate} 8.4% Sodium Bicarbonate ( pH ≈ 8.0 \text{pH} \approx 8.0 pH ≈ 8.0 ), ampicillin sodium ( pH ≈ 9.0 \text{pH} \approx 9.0 pH ≈ 9.0 ), or cefepime—the excess hydroxyl ions strip protons from the amine moiety, converting the drug into its uncharged free base ( [ B ] [\text{B}] [ B ] ), which rapidly precipitates as a milky cloud.
2. Co-Solvent Dilution Collapse (Water Dilution Shock)
Lipophilic drugs that cannot be solubilized through salt formation alone are commercially formulated with non-aqueous co-solvents (such as propylene glycol, ethanol, polyethylene glycol 400, or benzyl alcohol). These organic co-solvents disrupt the hydrogen-bonding matrix of water, decreasing the dielectric constant of the solvent and boosting drug solubility by thousands of times.
Representative Co-Solvent Formulations: Diazepam ( 40 % 40\% 40% propylene glycol, 10 % 10\% 10% ethanol), Lorazepam ( 80 % 80\% 80% propylene glycol, 18 % 18\% 18% polyethylene glycol 400), Digoxin ( 40 % 40\% 40% propylene glycol, 10 % 10\% 10% ethanol), Paclitaxel (Cremophor EL and 50 % 50\% 50% ethanol).
The Collapse Mechanism: When a co-solvent vial is injected rapidly into an aqueous large-volume parenteral bag (such as normal saline or dextrose), the co-solvent is instantly diluted throughout the bulk water. As the local organic solvent concentration falls below the critical solubilization concentration , the thermodynamic activity of the lipophilic drug spikes, causing the solute to crash out of solution as microscopic or visible flakes.
Important
Lorazepam Compounding Specifics: Lorazepam injection, formulated in propylene glycol and polyethylene glycol 400, is prone to precipitating when diluted. Its labeling directs dilution with an equal volume of a compatible diluent immediately before IV injection. For continuous infusions, take the concentration, diluent and container from a compatibility reference, because lorazepam's solubility depends on concentration. Inspect the infusion regularly for haze or crystals.
3. Gas Evolution (Effervescence)
Certain sterile admixtures produce gas through acid-base chemical reactions. A classic example is Ceftazidime for injection . Commercial ceftazidime vials are dry-blended with sodium carbonate excipient. When reconstituted with sterile diluent, an acid-base neutralization occurs between the acidic ceftazidime and the carbonate ion, releasing significant volumes of carbon dioxide ( CO 2 \text{CO}_2 CO 2 ) gas . Compounding personnel must use venting needles or specialized pressure-relief transfer systems to equilibrate internal vial pressure, preventing aerosolized spray or stoppers violently dislodging.
Chemical Incompatibilities: Covalent Degradation Pathways ┌────────────────────────────────────────────────────────────────────────────────────────┐
- │ PRIMARY CHEMICAL DEGRADATION PATHWAYS │
- ├────────────────────────────┬─────────────────────────────┬─────────────────────────────┤
- │ HYDROLYSIS │ OXIDATION │ PHOTODEGRADATION │
- ├────────────────────────────┼─────────────────────────────┼─────────────────────────────┤
- │ • Nucleophilic water attack│ • Free-radical auto-ox │ • Photon-induced cleavage │
- │ • Cleaves beta-lactam rings│ • Attacks phenols, catechols│ • Cleaves nitroprusside Fe-CN│
- │ • Hydrolyzes ester/amides │ • Catalyzed by Fe3+, Cu2+ │ • Generates toxic CYANIDE │
- │ • Accelerated by heat & pH │ • Forms colored quinones │ • Requires immediate foil / │
- │ • Stabilized by cold / dry │ • Shield via bisulfite/EDTA │ amber light shielding │
- └────────────────────────────┴─────────────────────────────┴─────────────────────────────┘
- 1. Hydrolysis
Hydrolysis is the nucleophilic cleavage of a covalent chemical bond by water molecules or hydroxyl ions ( OH − \text{OH}^- OH − ):
Beta-Lactam Ring Hydrolysis: Penicillins, cephalosporins, and carbapenems contain a strained, four-membered beta-lactam ring. Nucleophilic attack by water opens the ring, generating therapeutically inactive and potentially allergenic penicilloic acid derivatives. Ampicillin is exceptionally unstable in aqueous solution, exhibiting rapid, concentration-dependent self-catalyzed dimerization and ring-opening hydrolysis within hours.
Ester and Amide Cleavage: Ester linkages (such as in remifentanil, esmolol, procaine, and methylprednisolone sodium succinate) are cleaved into corresponding carboxylic acids and alcohols.
Thermodynamic Dependencies: Hydrolysis reaction rates follow the Arrhenius relationship and the Q 10 Q_{10} Q 10 rule : the degradation rate typically doubles or triples for every 10 ∘ C 10^\circ\text{C} 1 0 ∘ C rise in temperature. Hydrolysis is also strongly pH-dependent, exhibiting a characteristic V-shaped or U-shaped pH-rate profile with a specific pH of maximum stability (typically pH 4.0 to 7.0 \text{pH } 4.0\text{ to }7.0 pH 4.0 to 7.0 ).
2. Auto-Oxidation
Oxidation is the removal of electrons from a molecule, often initiated by molecular oxygen ( O 2 \text{O}_2 O 2 ) and mediated via free-radical chain mechanisms (initiation, propagation, termination). Trace multivalent transition metal impurities (such as Fe 3 + \text{Fe}^{3+} Fe 3 + and Cu 2 + \text{Cu}^{2+} Cu 2 + ) catalyze single-electron transfers that generate reactive hydroxyl and superoxide radicals.
Susceptible Functional Groups: Catecholamines (epinephrine, norepinephrine, dopamine, isoproterenol), phenolic compounds (morphine, acetaminophen), and sulfhydryl-containing moieties (cysteine).
Visual Manifestation: Oxidation of catecholamines yields colored ortho-quinones, which polymerize into pink, amber, or brown adrenochrome pigments. Any discolored catecholamine infusion must be immediately condemned and discarded.
Formulation Protection Strategies:
Sacrificial Antioxidants: Sodium metabisulfite, sodium bisulfite, sodium sulfite (act as preferred electron donors, scavenging radicals).
Metal Chelating Agents: Disodium edetate (EDTA), which complexes trace catalytic transition metal ions into unreactive coordination spheres.
Headspace Sparging: Bubbling high-purity inert gas (nitrogen or argon) through the liquid and displacing ambient air from the vial headspace during packaging.
3. Photodegradation (Photolysis)
Photolysis occurs when a drug molecule absorbs ultraviolet or visible electromagnetic photons, promoting ground-state electrons to excited singlet or triplet states that undergo homolytic bond cleavage or free-radical generation.
Caution
Fatal Photolysis: Sodium Nitroprusside: Sodium nitroprusside ( Na 2 [ Fe(CN) 5 NO ] \text{Na}_2[\text{Fe(CN)}_5\text{NO}] Na 2 [ Fe(CN) 5 NO ] ) is acutely photosensitive. Absorption of ambient light triggers photochemical cleavage of iron-cyanide coordination bonds, releasing lethal free cyanide ions and nitric oxide. As photolytic breakdown progresses, the normal reddish-brown solution turns dark orange, blue, or emerald green. Nitroprusside infusions must be immediately encased in opaque light-protective covers (amber plastic sleeves or aluminum foil) during preparation and clinical administration.
Other Photosensitive Therapeutics: Dacarbazine (turns pink upon photolysis), Amphotericin B deoxycholate, Phytonadione (vitamin K 1 \text{K}_1 K 1 ), Doxycycline, and Furosemide.
Container-Solution Interactions: Sorption & DEHP Leaching Phenomena
Parenteral containers and administration tubing are manufactured from specialized polymers. When compounded drugs contact polymeric surfaces, two distinct physical phenomena can compromise clinical safety and dosing accuracy: SORPTION (Loss of Drug from Solution) LEACHING (Extraction of Toxic Plasticizer)
- ┌──────────────────────────────────────────────┐ ┌──────────────────────────────────────────────┐
- │ ADSORPTION: Surface adhesion of drug │ │ PVC matrix contains 30-40% unbound DEHP │
- │ molecules onto plastic / glass walls. │ │ plasticizer to impart flexibility. │
- │ │ │ │
- │ ABSORPTION: Lipophilic drug dissolves into │ │ Surfactants (Cremophor EL, Polysorbate 80) │
- │ and penetrates the polymeric bulk matrix. │ │ & Lipids dissolve and LEACH DEHP INTO CSP! │
- ├──────────────────────────────────────────────┤ ├──────────────────────────────────────────────┤
- │ HIGH-RISK DRUGS: │ │ TOXICITIES: │
- │ • Nitroglycerin (up to 80% lost in PVC!) │ │ • Hepatotoxicity, chemical peritonitis │
- │ • Diazepam, Amiodarone, Lorazepam │ │ • Endocrine disruption & reproductive defect │
- │ • Regular Insulin (surface adsorption) │ │ • Neonatal / pediatric male testicular harm │
- └──────────────────────────────────────────────┘ └──────────────────────────────────────────────┘
- 1. Sorption Phenomena: Adsorption vs. Absorption
Adsorption (Surface Effect): Drug molecules bind electrostatically or via Van der Waals forces directly onto the internal fluid-contact surface of the container or IV tubing.
Regular Human Insulin: Readily adsorbs onto both borosilicate glass and plastic polymers. When initiating continuous regular insulin infusions, the tubing line must be primed and permitted to stand briefly to saturate available surface adsorption binding sites, ensuring steady-state delivery.
Absorption (Matrix Penetration): Lipophilic, unionized drug molecules physically dissolve into the polymer matrix of standard polyvinyl chloride (PVC) containers and tubing, diffusing away from the fluid pathway.
Nitroglycerin: Up to 80 % 80\% 80% of a nitroglycerin dose is rapidly absorbed into standard plasticized PVC infusion tubing. Administering nitroglycerin via standard PVC sets results in profound underdosing and acute hypertensive crises. Nitroglycerin must be compounded exclusively in non-PVC containers (polyolefin, glass) and infused through dedicated non-PVC, non-absorbing administration sets.
Other High-Sorption Drugs: Amiodarone, Diazepam, Lorazepam, Tacrolimus, Carmustine.
2. DEHP Plasticizer Leaching Mechanics
Standard PVC is an inherently rigid, brittle polymer. To manufacture flexible IV bags and pliable tubing sets, manufacturers incorporate up to 30 % 30\% 30% to 40 % 40\% 40% by weight of a chemical plasticizer: di(2-ethylhexyl) phthalate (DEHP) . Crucially, DEHP is not chemically crosslinked or covalently bound to the PVC polymer chains; it is merely suspended within the interstitial polymeric spaces.
Extraction Catalysts: Lipophilic formulation components, surfactant solubilizers, and intravenous fat emulsions act as organic extraction solvents that pull lipophilic DEHP out of the PVC matrix directly into the drug solution.
Polyoxyethylated Castor Oil (Cremophor EL): Formulating surfactant for Paclitaxel and Teniposide; extracts massive quantities of DEHP.
Polysorbate 80 (Tween 80): Surfactant present in Docetaxel and Amiodarone.
Intravenous Fat Emulsions (IVFE / TNAs): Lipid triglycerides readily dissolve and extract DEHP.
Clinical Toxicology of DEHP: DEHP is an endocrine disruptor, hepatotoxin, and peroxisome proliferator. It induces developmental male reproductive tract toxicity (atrophy of seminiferous tubules and suppressed testosterone production). Neonates, pediatric intensive care patients, and patients undergoing chronic transfusions or lifelong parenteral nutrition face profound risks from DEHP bioaccumulation.
3. Non-PVC Polymeric Alternatives
To prevent both sorption loss and DEHP leaching, modern sterile compounding utilizes advanced inert contact materials:
Polyolefin (Polypropylene / Polyethylene Copolymers): Thermoplastic material containing zero plasticizers, zero DEHP, and minimal drug sorption. Standard for nitroglycerin, amiodarone, and paclitaxel infusions.
Ethylene Vinyl Acetate (EVA): Highly flexible, DEHP-free polymer used universally for compounding total parenteral nutrition (TPN) and total nutrient admixture (TNA) bags.
Polyethylene-Lined Administration Sets: Feature a co-extruded structure consisting of a flexible PVC outer jacket for kink-resistance and durability, bonded to an inert inner liner of pure polyethylene that forms the actual fluid-contact lumen.
Type I Borosilicate Glass: Chemically inert and impermeable, but requires vented IV administration sets to allow air displacement.
In-Line Filtration Standards & Pore Sizing Architecture
In-line intravenous filters are critical physical barriers that capture particulate matter, microbial bioburden, endotoxin-bearing cell fragments, and accidental precipitates before they reach the patient's vascular bed.
Filter Rating Membrane Architecture & Materials Clinical Applications Contraindications & Mechanical Limits
0.22 μ m 0.22\,\mu\text{m} 0.22 μ m (or 0.2 μ m 0.2\,\mu\text{m} 0.2 μ m ) Hydrophilic polyethersulfone (PES), nylon, or PVDF; sterilizing-grade retention Non-lipid crystalloid solutions, 2-in-1 parenteral nutrition, aqueous antibiotic infusions NEVER use with lipid emulsions (droplets > 0.22 μ m > 0.22\,\mu\text{m} > 0.22 μ m clog pores, causing membrane rupture or emulsion cracking)
1.2 μ m 1.2\,\mu\text{m} 1.2 μ m High-porosity hydrophilic PES membrane 3-in-1 Total Nutrient Admixtures (TNAs) and pure Intravenous Fat Emulsions (IVFE) Allows intact lipid globules ( < 0.5 μ m < 0.5\,\mu\text{m} < 0.5 μ m ) to pass while retaining large unstable oil aggregates ( > 1.2 μ m > 1.2\,\mu\text{m} > 1.2 μ m ), Candida hyphae, and precipitates
5.0 μ m 5.0\,\mu\text{m} 5.0 μ m Stainless steel mesh or depth filter needle / filter straw Aspiration from glass ampules during compounding; select complex biologicals Used during compounding withdrawal only; must be exchanged for a regular non-filter needle prior to injection
High-Risk Incompatibility Reference Matrix
Drug Substance Incompatibility Classification Trigger Mechanism Clinical Hazard Required Compounding & Delivery Strategy
Sodium Phenytoin Physical (Precipitation) Acidic diluent ( D 5 W D_5W D 5 W / saline with pH < 10 \text{pH} < 10 pH < 10 ) Microvascular pulmonary emboli; loss of antiepileptic control Dilute ONLY in 0.9 % NaCl 0.9\%\,\text{NaCl} 0.9% NaCl to a final concentration of at least 5 mg/mL 5\,\text{mg/mL} 5 mg/mL per labeling; give promptly through an in-line 0.22 to 0.55 μ m 0.22\text{ to }0.55\,\mu\text{m} 0.22 to 0.55 μ m filter
Sodium Nitroprusside Chemical (Photolysis) Ambient light exposure Cleaves iron-cyanide bonds, generating lethal free cyanide Immediate light-protective opaque wrapping (amber wrap or aluminum foil) upon preparation
Nitroglycerin Physical (Sorption) Contact with plasticized PVC polymer Up to 80 % 80\% 80% dose loss into tubing matrix; hypertensive crisis Compound in glass or polyolefin containers; use non-PVC, non-absorbing administration sets
Paclitaxel Chemical / Physical (Leaching) Cremophor EL surfactant extracts DEHP from PVC Severe DEHP toxicity (hepatotoxicity, reproductive harm) Prepare in non-PVC containers (polyolefin); infuse via polyethylene-lined tubing with a 0.22 μ m 0.22\,\mu\text{m} 0.22 μ m in-line filter
Furosemide Physical (Precipitation) Mixing with acidic solutions ( pH < 7.0 \text{pH} < 7.0 pH < 7.0 ) Insoluble free acid precipitation; vascular line occlusion Avoid co-infusion with acidic medications (e.g., dopamine, midazolam, milrinone)